Kedar Upadhye appointed as new CFO of Biocon Biologics

New Delhi: Kedar Upadhye is appointed as the new Chief Financial Officer (CFO) of Biocon Biologics effective 31st October 2023. He brings with him over 23 years of experience in senior global leadership roles spanning Corporate Finance, Strategy, Accounting, FP&A, Business Finance, Governance and Investor Relations at leading Pharma, Energy and FMCG players such as Cipla, Dr. Reddy’s, PepsiCo, and Thermax.

He joins us from ReNew Energy Global Plc, a NASDAQ-listed decarbonization & renewable energy company, where he was the Chief Financial Officer (CFO). Prior to ReNew, Kedar was the Global CFO at Cipla where he was instrumental in setting up a strong global finance footprint with a focus on capital allocation, strategic partnership with the business, governance, and risk management in addition to driving the organization towards the next level of growth and delivering a superior return profile. He has a proven track record of overseeing value creation, strengthening investor relations and acting as an enabler of business.

“I am delighted to welcome Kedar to Biocon Biologics. He joins us at an inflection point in our journey to become a leading global biosimilars company as we look to consolidate and unlock value in the acquired business. I am confident that he will build further on the strong foundation and with his expertise and experience work closely with all stakeholders to drive growth and deliver on our business goals,” said Shreehas Tambe, CEO & Managing Director, Biocon Biologics.

Kedar Upadhye, the newly appointed CFO, Biocon Biologics Ltd, said “I would like to thank the Board of Directors and Leadership Team of Biocon Biologics for placing their trust in me and I am extremely excited to join the Company at an important point in its growth trajectory. I look forward to working with the Biocon Biologics team in an enriching journey to build a global biosimilars business which delivers strong, sustainable and profitable growth.”

Current CFO, MB Chinappa will take on a Strategic Finance Role at Biocon Group. These leadership changes will be effective October 31, 2023.Chinappa has served as CFO of Biocon Biologics since his appointment in January 2020 and has played an integral role in developing business strategy and enabling profitable growth. He has helped secure over $500M in Private Equity investment and was instrumental in the Company’s recent $3B+ acquisition of Viatris’ global biosimilars business in 2022 and its strategic vaccines partnership with the Serum Institute of India.

Given Chinappa’s deep understanding and experience at each of the Group Companies’ businesses during his 24-year tenure with Biocon Group, he will be moving to a strategic finance role and will work with Peter Bains, the recently appointed Group CEO, Biocon Limited.

Shreehas Tambe said “I would like to thank Chinappa for his immense contribution to Biocon Biologics over the past 3 years and to the Biocon Group for more than two decades. He has successfully built a strong foundation of fiscal prudence, financial governance and risk management. Chinappa has played an invaluable role in the multi-billion-dollar acquisition of Viatris’ global biosimilars business and set up the organization for success.

Peter Bains, Group CEO, Biocon Limited, said “I look forward to working closely with Chinappa in his new role as we look to identify and leverage synergies across the Biocon Group and create further value for all stakeholders. Having worked at all Group Companies, he is uniquely positioned for this role.”